StockData
Korsana Biosciences, Inc. logo

Korsana Biosciences, Inc. (KRSA) stock

KRSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30493% above fair value
$32.50−0.18 (-0.55%)

Close on Nov 17, 2026Market cap $152.14MP/E –Yield –

Korsana Biosciences profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Korsana Biosciences's profit margin for the twelve months ending Jun 30, 2026 was -353.0%. For fiscal 2025 it was -170.1%, against -152.8% the year before. The highest annual figure on record is -152.8% in fiscal 2024.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-170.1%−17.3
FY2024Dec 31, 2024-152.8%+14688.2
FY2022Dec 31, 2022-14841.1%−13530.9
FY2021Dec 31, 2021-1310.2%+2078.4
FY2020Dec 31, 2020-3388.6%−659.3
FY2019Dec 31, 2019-2729.3%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q4 FY2025Dec 31, 2025-78.0%−107.3
Q3 FY2025Sep 30, 2025-111.5%+261.1
Q2 FY2025Jun 30, 2025-348.4%+4026.8
Q1 FY2025Mar 31, 2025-1764.2%+61.1
Q4 FY2024Dec 31, 202429.3%+2050.9
Q3 FY2024Sep 30, 2024-372.7%+2871.6
Q2 FY2022Jun 30, 2022-4375.2%−3835.8
Q1 FY2022Mar 31, 2022-1825.3%+9390.8
Q4 FY2021Dec 31, 2021-2021.6%+12435.6
Q3 FY2021Sep 30, 2021-3244.3%+1458.7
Q2 FY2021Jun 30, 2021-539.4%+2068.6
Q1 FY2021Mar 31, 2021-11216.1%−9221.3
Q4 FY2020Dec 31, 2020-14457.1%−12697.9
Q3 FY2020Sep 30, 2020-4703.0%−2749.0
Q2 FY2020Jun 30, 2020-2608.0%−626.8
Q1 FY2020Mar 31, 2020-1994.9%–
Q4 FY2019Dec 31, 2019-1759.3%–
Q3 FY2019Sep 30, 2019-1954.0%–
Q2 FY2019Jun 30, 2019-1981.2%–

More Korsana Biosciences figures

See a number that looks wrong?